Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus Inc. CEO Garo H. Armen received 4,251 shares of common stock as payment for his salary for the pay period ending February 7, 2025, while also disposing of 137,568 shares.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 4,251 shares of Agenus common stock on February 7, 2025, as compensation in lieu of cash salary.
• The stock was issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and was fully vested upon issuance.
• The price of the stock was $3.50 per share, which was the closing price of Agenus common stock on February 7, 2025.
• Armen also disposed of 137,568 shares of common stock.
• Armen indirectly owns 31,298 shares through IRA accounts and 28,950 shares as trustee and general partner.

Sentiment

Score: 6

Explanation: Neutral sentiment. The CEO taking stock in lieu of salary can be seen as a positive sign of confidence, but the disposal of shares introduces uncertainty.

Positives

• The CEO's decision to take salary in stock demonstrates confidence in the company's future.
• The stock was issued under the company's equity incentive plan, aligning the CEO's interests with those of shareholders.

Negatives

• The disposal of 137,568 shares by Armen could be interpreted negatively by the market.

Risks

• The market may react negatively to the disposal of a large number of shares by the CEO.
• Continued reliance on stock-based compensation could dilute existing shareholders.

Industry Context

In the biotech industry, it is not uncommon for executives to receive stock options or grants as part of their compensation packages. This aligns their interests with the long-term success of the company. However, the disposal of shares could raise concerns if not properly explained.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, especially in the biotech sector.
• Comparing Agenus' executive compensation structure to companies like Gilead Sciences, Amgen, or Regeneron could provide a benchmark.
• The percentage of compensation paid in stock versus cash can vary widely based on company size, stage of development, and financial performance.

Stakeholder Impact

• Shareholders may be concerned about the disposal of shares by the CEO.
• Employees may view the CEO taking stock as a positive sign of leadership's commitment.

Key Dates

Keywords

Agenus, Garo Armen, stock, salary, compensation, Form 4, beneficial ownership, equity incentive plan